StreetInsider.com News Articles

Form 25-NSE KINETA, INC./DE Filed by: Nasdaq Stock Market LLC

Tue, 15 Oct 2024 09:49:00 -0400

si-local-file:///var/storage/secattach/20241015/23836013.html

Form 25-NSE KINETA, INC./DE Filed by: Nasdaq Stock Market LLC

Tue, 15 Oct 2024 09:49:00 -0400

si-local-file:///var/storage/secattach/20241015/23836013.html

Form 8-K KINETA, INC./DE For: Oct 08

Tue, 08 Oct 2024 09:05:00 -0400

si-local-file:///var/storage/secattach/20241008/23814098.html

Form 8-K KINETA, INC./DE For: Oct 08

Tue, 08 Oct 2024 09:05:00 -0400

si-local-file:///var/storage/secattach/20241008/23814098.html

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Tue, 08 Oct 2024 09:00:00 -0400

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

The company will present additional scientific data in 2024 at an upcoming scientific meeting.

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Fri, 04 Oct 2024 09:05:00 -0400

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually.